BMS-986447 / BMS, Recursion Pharma - LARVOL DELTA

Exscientia Business Update for First Quarter 2024 (Businesswire) - "Based on patient unmet need, supporting preclinical data and the unique precision designed properties of Exscientia’s MALT1 inhibitor, EXS73565 (‘565), the Company is preparing to submit an IND or CTA in the second half of 2024 to study ‘565 in a Phase 1/2 clinical trial in B-cell malignancies, including CLL, which Exscientia expects to launch in early 2025....EXS4318 (‘4318), a potential first-in-class PKC-theta inhibitor designed by Exscientia and in-licensed by Bristol Myers Squibb, has shown positive early results in its Phase 1 study and has the potential to be a first-in-class immunology drug...Exscientia retains rights to receive milestone payments and potential royalties for ‘4318."

IND • Licensing / partnership • New P1/2 trial • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Bristol-Myers Squibb | Recruiting ➔ Completed | Trial completion date: Aug 2024 ➔ Nov 2023

Trial completion • Trial completion date

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Bristol-Myers Squibb | Trial completion date: Aug 2023 ➔ Aug 2024 | Trial primary completion date: Aug 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting

Enrollment open